Application Note: Multiplexed Antibody Characterization

Exquisite binding specificity of antibody therapeutics makes it challenging to test them in other species during pre-clinical testing. Engineering lead candidates with the ability to cross react with the target antigen from multiple animal species overcomes this hurdle.

This case study illustrates how XOMA used the multiplexing capabilities of the Intellicyt platform to incorporate cross species reactivity of antibodies into the screening phase of the discovery process.